Voyager Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase
Rhea-AI Summary
Voyager Therapeutics (Nasdaq: VYGR), a biotechnology company focused on neurogenetic medicines, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase. The company will engage in a fireside chat on August 14, 2024, at 9:30 a.m. ET.
Investors and interested parties can access a webcast of the presentation through the Investors section of Voyager's website at ir.voyagertherapeutics.com. For those unable to attend live, a replay of the webcast will be available on the company's website for a minimum of 30 days following the event.
Positive
- None.
Negative
- None.
News Market Reaction – VYGR
In the trading session that priced this news, VYGR declined 14.04%, reflecting a significant negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LEXINGTON, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase on August 14, 2024, at 9:30 a.m. ET.
A webcast of the presentation may be accessed from the Investors section of Voyager’s website at ir.voyagertherapeutics.com. A replay of the webcast will be archived on the Company's website for at least 30 days.
About Voyager Therapeutics
Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc.; and Sangamo Therapeutics, Inc. For more information, visit www.voyagertherapeutics.com.
Voyager Therapeutics® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc.
Contacts
Trista Morrison, NACD.DC, tmorrison@vygr.com
Investors: Adam Bero, Ph.D., abero@kendallir.com
Media: Brooke Shenkin, brooke@scientpr.com
